Atea Pharmaceuticals (AVIR) Insider Murphy Sells 29,600 Shares

Polly Murphy Executes AVIR Share Sale

Polly Murphy sold 29,600 shares of Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR) on June 18, 2026. This transaction forms part of a wider pattern of recent executive moves at the clinical-stage biopharmaceutical firm, unfolding alongside several other buying and selling reports filed on the exact same day.

Busy Day of AVIR Insider Transactions

The June 18, 2026 filing window brought a flurry of activity from multiple company insiders beyond Murphy. Bruce Polsky picked up 29,600 shares, while Franklin Berger was active on both sides by acquiring 29,600 shares and separately selling 29,600 shares. Bruno Lucidi also logged a pair of transactions, selling 29,600 shares while picking up 26,700 shares. Rounding out the group, Howard Berman added 37,700 shares on the same date. These diverse moves highlight a wave of individual portfolio adjustments among key figures at the firm.

AVIR Stock Price and Market Standing

The company shares recently traded around $4.39. The equity moves within a 52-week band stretching from a low of $2.78 up to a peak of $6.45. Market participants continue to monitor how these internal executive trades align with broader shifts in the wider biotechnology sector.

Analysts Set New Price Targets

Analyst coverage from Morgan Stanley provides additional context for market watchers. On August 13, 2026, Morgan Stanley maintained its Equal-Weight rating on the stock while setting a price target of $7.00, stepping up from a prior target of $6.00. Across the broader professional community, opinion stands on three analyst views that point toward a mean price target of $9.41.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and developing oral antiviral medicines for patients battling serious viral illnesses. Headquartered in Boston, Massachusetts, the firm works on treatments targeting conditions such as hepatitis C and chronic infections through proprietary nucleoside and nucleotide platforms.

What to Watch Next for AVIR

Investors tracking Atea Pharmaceuticals can look toward the next scheduled earnings report on November 11, 2026, for further financial updates. Form 4 insider transaction reports offer a transparent look at executive decisions, though individual sales or purchases do not necessarily signal a broader directional shift for the stock.